REVIEW ARTIKEL: TERAPI POTENSIAL UNTUK INFEKSI SARS-CoV-2 PADA COVID-19

FAHRINA NUR FADHILAH, YEDI HERDIANA

Abstrak


Wabah SARS-CoV-2 pertama kali muncul di Wuhan, Provinsi Hubei, China, pada akhir tahun 2019. Infeksi yang diakibatkan oleh jenis baru Coronavirus ini kemudian ditetapkan sebagai pandemik dunia oleh World Health Organization (WHO), dengan penyakit yang ditimbulkan disebut sebagai Coronavirus Disease 2019 (COVID-19). Infeksi SARS-CoV-2 menimbulkan gejala seperti gejala yang timbul pada pneumonia. Hingga saat ini, berbagai penelitian untuk menemukan terapi potensial yang tepat untuk menangani COVID-19 masih terus dilakukan. Beberapa kandidat terapi seperti Redemsivir, Lopinavir/Ritonavir, Arbidol, Chloroquine, Hydroxychloroquine, serta inhibitor protease telah banyak diteliti. Review artikel ini bertujuan mengumpulkan informasi dari berbagai penelitian mengenai terapi potensial untuk COVID-19.

Kata kunci: SARS-CoV-2, COVID-19, terapi COVID-19.


Teks Lengkap:

PDF

Referensi


Blaising, J., Polyak, S. J., & Pécheur, E. (2014). Arbidol as a broad-spectrum antiviral : An update. ANTIVIRAL RESEARCH, 107, 84–94. https://doi.org/10.1016/j.antiviral.2014.04.006

Brüssow, H. (2020) ‘The Novel Coronavirus – A Snapshot of Current Knowledge’, Microbial Biotechnology, 13(3), pp. 607–612. doi: 10.1111/1751-7915.13557.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., … Wang, C. (2020). new england journal. 1787–1799.https://doi.org/10.1056/NEJMoa2001282

Cui, J., Li, F. and Shi, Z. L. (2019) ‘Origin and evolution of pathogenic coronaviruses’, Nature Reviews Microbiology. Springer US, 17(3), pp. 181–192. doi: 10.1038/s41579-018-0118-9.

Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., & Hong, Z. (2020). Arbidol combined with LPV / r versus LPV / r alone against Corona Virus Disease 2019 : A retrospective cohort study. Journal of Infection, xxxx.https://doi.org/10.1016/j.jinf.2020.03.002

Drosten, C. et al. (2003) ‘Identification of a novel coronavirus in patients with severe acute respiratory syndrome’, New England Journal of Medicine, 348(20), pp. 1967–1976. doi: 10.1056/NEJMoa030747.

Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough : Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 14(1), 72–73. https://doi.org/10.5582/bst.2020.01047

Gautret, P., Lagier, J., Parola, P., Doudier, B., Courjon, J., Scola, B. La, Rolain, J., Brouqui, P., Raoult, D., Mailhe, M., Doudier, B., & Courjon, J. (2020). Department of Virology , Biological and Pathological Center , Centre Hospitalier. International Journal of Antimicrobial Agents, 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Glowacka, I. et al. (2011) ‘Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response ᰔ’, JOURNAL OF VIROLOGY 85(9), pp. 4122–4134. doi: 10.1128/JVI.02232-10.

Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020). The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry, 295(15), 4773–4779. https://doi.org/10.1074/jbc.AC120.013056

Huang, C. et al. (2020) ‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China’, The Lancet, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., & Matsuyama, S. (2012). Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry. Journal of Virology, 86(12), 6537–6545. https://doi.org/10.1128/jvi.00094-12

Kirchdoerfer, R. N. et al. (2016) ‘spike protein’, Nature. Nature Publishing Group. doi: 10.1038/nature17200.

Li, F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual Review of Virology, 3(1), 237–261. https://doi.org/10.1146/annurev-virology-110615-042301

Lim, J., Jeon, S., Shin, H., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K., Kang, Y. M., Lee, B., & Park, S. (2020). Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea : the Application of Lopinavir / Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci.35(6), 1–6.

Lu, G., Wang, Q. and Gao, G. F. (2015) ‘Bat-to-human : spike features determining “ host jump ” of MERS-CoV , and beyond’, Trends in Microbiology. Elsevier Ltd, 23(8), pp. 468–478. doi: 10.1016/j.tim.2015.06.003.

Menachery, V. D. et al. (2020) ‘crossm Trypsin Treatment Unlocks Barrier for Zoonotic Bat’, Journal of Virology, 94(5), pp. 1–15.

Rolain, J., Colson, P., & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial , fungal and viral infections in the 21st century. International Journal of Antimicrobial Agents 30, 297–308. https://doi.org/10.1016/j.ijantimicag.2007.05.015

Woo, P. C. Y. et al. (2012) ‘Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavi’, Journal of Virology, 86(7), pp. 3995–4008. doi: 10.1128/jvi.06540-11.

Yamaya, M., Shimotai, Y., Hatachi, Y., Lusamba Kalonji, N., Tando, Y., Kitajima, Y., Matsuo, K., Kubo, H., Nagatomi, R., Hongo, S., Homma, M., & Nishimura, H. (2015). The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. Pulmonary Pharmacology and Therapeutics, 33, 66–74. https://doi.org/10.1016/j.pupt.2015.07.001

Yethindra, V. (2020). Role of GS-5734 ( Remdesivir ) in inhibiting SARS-CoV and MERS-CoV : The expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV) - VYTR hypothesis. Int. J. Res. Pharm. Sci., 11(1), 1–6.

Zhong, N. S. et al. (2003) ‘Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003’, Lancet, 362(9393), pp. 1353–1358. doi: 10.1016/S0140-6736(03)14630-2.




DOI: https://doi.org/10.24198/farmaka.v18i2.27872

DOI (PDF): https://doi.org/10.24198/farmaka.v18i2.27872.g14728

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved